LIT-001
LIT-001 is a small-molecule oxytocin receptor agonist and vasopressin receptor mixed agonist and antagonist that was first described in the literature in 2018. Along with TC OT 39 and WAY-267464, it is one of the first small-molecule oxytocin receptor agonists to have been developed. LIT-001 has greatly improved pharmacokinetic properties relative to oxytocin, reduces social deficits in animal models, and may have potential as a therapeutic agent in the treatment of social disorders like autism in humans. LIT-001 is similar in structure to TC OT 39. Compared to TC OT 39 and WAY-267464, LIT-001 has greater selectivity for the oxytocin receptor over the vasopressin V1A receptor. LIT-001 shows antagonism of the V1A receptor only at high concentrations. LIT-001 additionally acts as an agonist of the vasopressin V2 receptor, with this action occurring at similar concentrations as for the oxytocin receptor. This is unlikely to influence the oxytocin receptor-related behavioral ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]